93 related articles for article (PubMed ID: 7462389)
1. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome.
Quigley ME; Rakoff JS; Yen SS
J Clin Endocrinol Metab; 1981 Feb; 52(2):231-4. PubMed ID: 7462389
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels.
Judd SJ; Rakoff JS; Yen SS
J Clin Endocrinol Metab; 1978 Sep; 47(3):494-8. PubMed ID: 122409
[TBL] [Abstract][Full Text] [Related]
5. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.
Chang RJ; Mandel FP; Lu JK; Judd HL
J Clin Endocrinol Metab; 1982 Mar; 54(3):490-4. PubMed ID: 6799536
[TBL] [Abstract][Full Text] [Related]
6. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release.
Judd SJ; Rigg LA; Yen SS
J Clin Endocrinol Metab; 1979 Aug; 49(2):182-4. PubMed ID: 572372
[TBL] [Abstract][Full Text] [Related]
7. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
Barnes RB; Lobo RA
J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
[TBL] [Abstract][Full Text] [Related]
8. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
9. Prolactin release in polycystic ovary.
Falaschi P; del Pozo E; Rocco A; Toscano V; Petrangeli E; Pompei P; Frajese G
Obstet Gynecol; 1980 May; 55(5):579-82. PubMed ID: 6768043
[TBL] [Abstract][Full Text] [Related]
10. [Relation between hyperprolactinemia and polycystic ovary syndrome].
Hámori M; Szendei G; Kovács I; Somos P
Zentralbl Gynakol; 1987; 109(8):481-6. PubMed ID: 3111126
[TBL] [Abstract][Full Text] [Related]
11. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
12. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
[TBL] [Abstract][Full Text] [Related]
13. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
14. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
[TBL] [Abstract][Full Text] [Related]
16. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO.
Lobo RA; Granger L; Goebelsmann U; Mishell DR
J Clin Endocrinol Metab; 1981 Jan; 52(1):156-8. PubMed ID: 6778890
[TBL] [Abstract][Full Text] [Related]
17. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.
Rosen GF; Lobo RA
J Clin Endocrinol Metab; 1987 Nov; 65(5):891-5. PubMed ID: 3117832
[TBL] [Abstract][Full Text] [Related]
18. Prolactin levels in the polycystic ovary syndrome.
Milewicz A
J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
[TBL] [Abstract][Full Text] [Related]
19. Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome.
Kazer RR; Kessel B; Yen SS
J Clin Endocrinol Metab; 1987 Aug; 65(2):233-6. PubMed ID: 3597703
[TBL] [Abstract][Full Text] [Related]
20. Effects of LH suppression in polycystic ovary syndrome.
Fleming R; Black WP; Coutts JR
Clin Endocrinol (Oxf); 1985 Dec; 23(6):683-8. PubMed ID: 3938353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
